Gentian Diagnostics AS (OSL:GENT) Change In Receivables : kr-2.6 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Change In Receivables?

Gentian Diagnostics AS's change in receivables for the quarter that ended in Mar. 2025 was kr4.9 Mil. It means Gentian Diagnostics AS's Accounts Receivable declined by kr4.9 Mil from Dec. 2024 to Mar. 2025 .

Gentian Diagnostics AS's change in receivables for the fiscal year that ended in Dec. 2024 was kr-11.7 Mil. It means Gentian Diagnostics AS's Accounts Receivable increased by kr11.7 Mil from Dec. 2023 to Dec. 2024 .

Gentian Diagnostics AS's Accounts Receivable for the quarter that ended in Mar. 2025 was kr29.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Gentian Diagnostics AS's Days Sales Outstanding for the three months ended in Mar. 2025 was 60.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Gentian Diagnostics AS's liquidation value for the three months ended in Mar. 2025 was kr104.7 Mil.

Gentian Diagnostics AS Change In Receivables Historical Data

The historical data trend for Gentian Diagnostics AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Change In Receivables Chart

Gentian Diagnostics AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

0.86

1.12

-3.55

-1.20

-11.72

Gentian Diagnostics AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-4.25	0.38	13.87	-21.73	4.87

Gentian Diagnostics AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.6 Mil.

Gentian Diagnostics AS (OSL:GENT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Gentian Diagnostics AS's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.635	/	44.501	*	91
=	60.77

2. In Ben Graham's calculation of liquidation value, Gentian Diagnostics AS's accounts receivable are only considered to be worth 75% of book value:

Gentian Diagnostics AS's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	88.742	-	32.437	+	0.75 * 29.635	+	0.5 * 52.308
=	104.7

Gentian Diagnostics AS Change In Receivables Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Gentian Diagnostics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

6FK:Germany

Address

Bjornasveien 5, Moss, NOR, 1596

Website

https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.